SA521430328B1 - تركيبات وطرق لعلاج السرطان - Google Patents

تركيبات وطرق لعلاج السرطان

Info

Publication number
SA521430328B1
SA521430328B1 SA521430328A SA521430328A SA521430328B1 SA 521430328 B1 SA521430328 B1 SA 521430328B1 SA 521430328 A SA521430328 A SA 521430328A SA 521430328 A SA521430328 A SA 521430328A SA 521430328 B1 SA521430328 B1 SA 521430328B1
Authority
SA
Saudi Arabia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
protective element
protection element
Prior art date
Application number
SA521430328A
Other languages
Arabic (ar)
English (en)
Inventor
مايكل اي. جونج،
ديفيد ايه. ناثانسون،
حوناثن تسانج،
جودونج كيم،
لورينز يورنير،
بيتر ام. كلارك،
تيموثي اف. كلاوجيسي،
Original Assignee
ذا ريجينتس اوف ذا يونيفيرسيتى اوف كاليفورنيا.،
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ذا ريجينتس اوف ذا يونيفيرسيتى اوف كاليفورنيا.، filed Critical ذا ريجينتس اوف ذا يونيفيرسيتى اوف كاليفورنيا.،
Publication of SA521430328B1 publication Critical patent/SA521430328B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SA521430328A 2019-03-15 2021-09-15 تركيبات وطرق لعلاج السرطان SA521430328B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819322P 2019-03-15 2019-03-15
US201962904241P 2019-09-23 2019-09-23
PCT/US2020/022743 WO2020190765A2 (en) 2019-03-15 2020-03-13 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
SA521430328B1 true SA521430328B1 (ar) 2024-03-28

Family

ID=72521289

Family Applications (1)

Application Number Title Priority Date Filing Date
SA521430328A SA521430328B1 (ar) 2019-03-15 2021-09-15 تركيبات وطرق لعلاج السرطان

Country Status (17)

Country Link
US (3) US11377451B2 (cg-RX-API-DMAC7.html)
EP (1) EP3938354A4 (cg-RX-API-DMAC7.html)
JP (2) JP7474269B2 (cg-RX-API-DMAC7.html)
KR (1) KR102809395B1 (cg-RX-API-DMAC7.html)
CN (2) CN115215808B (cg-RX-API-DMAC7.html)
AU (1) AU2020241703B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021018295A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133688A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002409A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021013496A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210498A (cg-RX-API-DMAC7.html)
IL (1) IL286350A (cg-RX-API-DMAC7.html)
MX (1) MX2021011272A (cg-RX-API-DMAC7.html)
PH (1) PH12021552208A1 (cg-RX-API-DMAC7.html)
SA (1) SA521430328B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109662YA (cg-RX-API-DMAC7.html)
WO (1) WO2020190765A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240017986A (ko) * 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
KR102809395B1 (ko) 2019-03-15 2025-05-16 더 리전트 오브 더 유니버시티 오브 캘리포니아 암을 치료하기 위한 조성물 및 방법
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061299A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
WO2022061201A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022155311A1 (en) * 2021-01-14 2022-07-21 The Regents Of The University Of California Methods and systems for analysis of drug target engagement and treatment of cancer
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
US20240165132A1 (en) * 2021-05-12 2024-05-23 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN113307799B (zh) * 2021-05-21 2022-07-19 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
CA3233057A1 (en) * 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms
WO2023244639A1 (en) * 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors
US20260108524A1 (en) * 2022-10-14 2026-04-23 The Regents Of The University Of California Egfr inhibitors for treating lung cancer
WO2024102177A1 (en) * 2022-11-08 2024-05-16 The Regents Of The University Of California Combination therapies for the treatment of brain cancer
AU2024388187A1 (en) * 2023-11-27 2026-06-18 Katmai Pharmaceuticals, Inc. Compositions and methods for treating cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법
CN1854130B (zh) 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
WO2008046242A1 (fr) 2006-10-16 2008-04-24 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
EP2484678B1 (en) 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
ITPD20110091A1 (it) 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
CA3081443A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
WO2016123706A1 (en) * 2015-02-03 2016-08-11 Trillium Therapeutics Inc. Novel fluorinated derivatives as egfr inhibitors useful for treating cancers
CN105017163A (zh) 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
US10473255B2 (en) 2015-12-29 2019-11-12 Ge-Hitachi Nuclear Energy Americas Llc Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device
CA3008312A1 (en) 2016-01-06 2017-07-13 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as egfr inhibitors
CN106432202B (zh) 2016-09-22 2019-04-02 郑州大学第一附属医院 喹唑啉类衍生物及其应用
KR20240017986A (ko) * 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
KR102809395B1 (ko) * 2019-03-15 2025-05-16 더 리전트 오브 더 유니버시티 오브 캘리포니아 암을 치료하기 위한 조성물 및 방법
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061201A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061299A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
CA3233057A1 (en) * 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms
WO2023244639A1 (en) * 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors

Also Published As

Publication number Publication date
US20230115366A1 (en) 2023-04-13
CN115215808A (zh) 2022-10-21
KR20210151820A (ko) 2021-12-14
EP3938354A4 (en) 2022-12-28
IL286350A (en) 2021-10-31
BR112021018295A2 (pt) 2021-11-23
JP7789832B2 (ja) 2025-12-22
PH12021552208A1 (en) 2022-05-30
CR20210498A (es) 2022-01-11
CL2021002409A1 (es) 2022-06-17
US11377451B2 (en) 2022-07-05
AU2020241703B2 (en) 2026-02-05
JP7474269B2 (ja) 2024-04-24
JP2024102094A (ja) 2024-07-30
MX2021011272A (es) 2021-10-01
US20250145634A1 (en) 2025-05-08
WO2020190765A3 (en) 2020-11-26
EP3938354A2 (en) 2022-01-19
CN115215808B (zh) 2025-04-18
WO2020190765A2 (en) 2020-09-24
AU2020241703A1 (en) 2021-10-14
CN113811528A (zh) 2021-12-17
CO2021013496A2 (es) 2022-01-17
KR102809395B1 (ko) 2025-05-16
CA3133688A1 (en) 2020-09-24
SG11202109662YA (en) 2021-10-28
US20220064177A1 (en) 2022-03-03
JP2022526266A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
PH12021552208A1 (en) Compositions and methods for treating cancer
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
AU2018368731A8 (en) Combination therapies
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
MX2024009727A (es) Terapias de combinacion.
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
EA200970953A1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
WO2019197605A3 (en) Drug combinations for use in the treatment of ras-mutant cancer
MY152948A (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
MX2020003361A (es) Combinacion de un inhibidor parp y un antagonista de union al eje pd-1.
WO2009137543A3 (en) Methods for breast cancer screening and treatment
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
MX2019001132A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
AU2018271862A1 (en) Combination therapy
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
WO2020132560A3 (en) Compositions and methods for cancer therapy
PH12022552347A1 (en) Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
MX2023008375A (es) Composiciones farmacéuticas para tratar cánceres de mama y métodos de usos de estas.
MX2024000674A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2